peptide mapping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
=== Mass spectrometry === Previously, many studies used Mass Spectrometry (MS) in different fragmentation modes to detect AMPylated peptides. In responses to the distinctive fragmentation techniques, AMPylated protein sequences disintegrated at different parts of AMP. While electron transfer dissociation (ETD) creates minimum fragments and less complicated spectra, collision-induced dissociation (CID) and high-energy collision (HCD) fragmentation generate characteristic ions suitable for AMPylated proteins identification by generating multiple AMP fragments. Due to AMP's stability, peptide fragmentation spectra is easy to read manually or with search engines.
Thiobuscaline (TB), or 4-thiobuscaline (4-TB), also known as 3,5-dimethoxy-4-butylthiophenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to the psychedelic drug mescaline. It is the analogue of buscaline in which the butoxy group at the 4 position has been replaced with a butylthio group. The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist with similar effects and potential uses to those of Ariadne.
=== Diseases === Medical conditions associated with weight gain include hypothyroidism, Cushing's syndrome, Polycystic Ovary Syndrome (PCOS), and congestive heart failure. Medical conditions such as cancer, gastrointestinal illness, psychiatric disorders, infections, endocrine disorders, and neurologic disorders may lead to weight loss.
Sources: en.wikipedia.org
The melting points of branched-chain alkanes can be either higher or lower than those of the corresponding straight-chain alkanes, again depending on these two factors. More symmetric alkanes tend towards higher melting points, due to enthalpic effects when they form ordered crystals, and entropic effects when they form disordered crystals (e.g. neopentane).
== Use and effects == According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) and other publications, the dose and duration of 4-HO-DPT are unknown. At a dose of 20 mg orally, there were possibly threshold effects and nothing more. Per Shulgin, there were not enough observations to know what dose would result in activity or what the effects would be. However, the occurrence of threshold effects at a dose of 20 mg was suggestive that "something is nearby". Subsequently, 4-HO-DPT and its presumed prodrug 4-AcO-DPT have been encountered as novel designer drugs, substantiating the notion that more significant effects do indeed occur with 4-HO-DPT at sufficiently high doses. Based on user reports, 4-HO-DPT has an onset of 15 to 45 minutes, a duration of 5 to 8 hours, and produces hallucinogenic effects including psychedelic visuals among others.
=== Human Diseases and Gene Mutations === Greenspan has conducted various research projects directly on the molecular bases of human diseases. A collaborative study with a group at Jefferson Medical College showed mutations in the COL7A1 gene, for type VII collagen, to be the basis of the disabling and fatal skin disease dystrophic epidermolysis bullosa These studies also led to elucidation of the complete intron-exon structure of COL7A1 which at the time had more exons than any previously described gene. His lab was the first to clone and characterize the α1 chain of type V collagen and was also key in the first demonstration that mutations in a type V collagen gene can cause the heritable connective tissue disorder classic Ehers-Danlos syndrome. Accompanying and following these studies, the Greenspan lab has performed studies on collagen V genes and on the biosynthesis of type V collagen and on the molecular mechanisms whereby mutations in type V collagen result in defects in mammalian tissues. Their studies have also shown autoimmunity against type V collagen to be involved in organ transplant rejection and atherosclerosis, and that induction of immune tolerance to type V collagen can help ameliorate atherosclerosis. The Greenspan lab was also the first to clone and characterize the α3 chain of type V collagen and showed the α3(V) chain to be important to the functioning of certain highly specialized cell types and to be important to tumor growth and survival times in breast cancer.
Sources: en.wikipedia.org
== Oxidative bisulfite sequencing == 5-Methylcytosine and 5-hydroxymethylcytosine both read as a C in bisulfite sequencing. In oxidative bisulfite sequencing (oxBS), Tet is used to convert 5-hydroxymethylcytosine to 5-formylcytosine, which subsequently converts to uracil during bisulfite treatment. The only base that then reads as a C is 5‑methylcytosine, giving a map of the true methylation status in the DNA sample. Levels of 5‑hydroxymethylcytosine can also be quantified by measuring the difference between bisulfite and oxidative bisulfite sequencing. Another method, Tet-assisted oxidative bisulfite sequencing (TAB-Seq) by Chuan He at the University of Chicago, converts the bases differently: 5hmC reads as C, while 5mC and C both read as T. To achieve this, 5hmC bases are first "protected" by conversion to β-glucosyl-5-hydroxymethylcytosine (5gmC). The Tet enzyme is introduced to convert all 5mC to 5caC. Bisulfite then converts both C and 5caC into uracil. 5gmC will be read out like C in PCR amplification.
One study found that individuals with schizophrenia showed just a 7% prevalence of problematic drug use in the year prior to being interviewed and 21% reported problematic use some time before that. Wright and colleagues identified individuals with psychotic illnesses who had been in contact with services in the London borough of Croydon over the previous 6 months. Cases of alcohol or substance misuse and dependence were identified through standardized interviews with clients and keyworkers. Results showed that prevalence rates of dual diagnosis were 33% for the use of any substance, 20% for alcohol misuse only and 5% for drug misuse only. A lifetime history of any illicit drug use was observed in 35% of the sample.
=== Hair loss === Studies have reported that PRP is beneficial for alopecia areata and androgenetic alopecia and can be used as an alternative to minoxidil or finasteride. A review reported it to improve hair density and thickness in both genders. A minimum of 3 treatments, once a month for 3 months are recommended, and afterwards a 3-6 month period of continual appointments for maintenance. Factors that determine efficacy include number of sessions, double versus single centrifugation, age, gender, and the injection site.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.